ADC Therapeutics highlights ZYNLONTA growth opportunity in corporate presentation

• ADC Therapeutics highlighted ZYNLONTA growth ambitions, targeting a multi-billion-dollar US opportunity across 2L+ DLBCL and 2L+ indolent lymphomas.
• LOTIS-5 Phase 3 met its primary PFS endpoint: HR 0.73, p 0.0084; median PFS 6.14 months vs 4.73 months.
• Complete responses improved to 40% from 27%; 24-month CR durability 48.5% vs 16.7%.
• Overall survival showed no detriment: HR 0.96; median OS 12.19 months vs 12.16 months.
• Safety profile mixed: Grade 5 TEAEs 13.2% vs 4.6%; hematologic Grade ≥3 TEAEs higher with R-GemOx.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief on September 10, 2026, and is solely responsible for the information contained therein.